“Frequent hemodialysis as currently practiced may improve the lives of some but is not a cost-effective or practical solution to improving the physical health of most patients with end-stage kidney disease,” said Dr. Hall. “Faced with rising numbers of persons with progressive chronic kidney disease worldwide, we need to broadly consider innovative strategies beyond manipulating the dose of dialysis to substantially improve or preserve the physical capacity of patients with end-stage kidney disease,” he added.
Study co-authors include Brett Larive (Cleveland Clinic Foundation); Patricia Painter, PhD (University of Utah, Salt Lake City); George Kaysen, MD, PhD (University of California, Davis); Robert Lindsay, MD (University of Western Ontario and London Health Sciences Center, in Canada); Allen Nissenson, MD (DaVita, Inc.); Mark Unruh, MD (University of
Pittsburgh); Michael Rocco, MD (Wake Forest University School of Medicine); Glenn Chertow, MD (Stanford University School of Medicine); and the Frequent Hemodialysis Network Trial Group.
Disclosures: The Frequent Hemodialysis Network trials were supported by the National Institutes of Health (NIH), National Institutes of Diabetes and Digestive and Kidney Diseases, the Centers for Medicare and Medicaid Services, and the NIH Research Foundation. Contributors to the NIH Foundation in support of the Frequent Hemodialysis Network trials included Amgen, Baxter and Dialysis Clinics. Additional support was provided by DaVita, Dialysis Clinics, Fresenius Medical Care, Renal Advantage, Renal Research Institute, and Satellite Healthcare. Dr. Hall has received research support from Satellite Healthcare’s Norman Coplon extramural grant program. Dr. Kaysen has received research support from Dialysis Clinics, Inc. Dr. Nissenson is employed by DaVita, Inc. Dr. Unruh has received research support from Satellite Healthcare’s Norman Coplon extramural grant program, Dialysis Clinics, Inc. and Baxter Healthcare and has consulted for Merck, Sigma-Tau and Baxter Healthcare. Dr. Rocco has consulted for Amgen, Inc. and DaVita, Inc. Dr. Chertow is a member of the Board of Directors of Satellite Healthcare and the Scientific Advisory Board of DaVita, Inc. and has consulted for Amgen, Inc.